<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00687193</url>
  </required_header>
  <id_info>
    <org_study_id>A3921040</org_study_id>
    <nct_id>NCT00687193</nct_id>
  </id_info>
  <brief_title>Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan</brief_title>
  <official_title>A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690,550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the dose-response relationship of 5 dose of CP-690,550, compared to placebo for
      the treatment of signs and symptoms in patients with active RA who failed an adequate trial
      of therapy with at least 1 DMARD in a 12-week therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in painful and tender joint count; &gt;= 20% improvement in swollen joint count; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4 and 8</measure>
    <time_frame>Week 2, 4, and 8</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in painful and tender joint count; &gt;= 20% improvement in swollen joint count; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP)at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response</measure>
    <time_frame>Week 2, 4, 8 and 12</time_frame>
    <description>ACR50 response: greater than or equal to (&gt;=) 50 percent (%) improvement in painful and tender joint count; &gt;= 50% improvement in swollen joint count; and &gt;= 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP) at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>Week 2, 4, 8 and 12</time_frame>
    <description>ACR70 response: greater than or equal to (&gt;=) 70 percent (%) improvement in painful and tender joint count; &gt;= 70% improvement in swollen joint count; and &gt;= 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP) at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response</measure>
    <time_frame>Week 2, 4, 8 and 12</time_frame>
    <description>ACR90 response: greater than or equal to (&gt;=) 90 percent (%) improvement in painful and tender joint count; &gt;= 90% improvement in swollen joint count; and &gt;= 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP) at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Based on 28-Joints Count Using C-reactive Protein [DAS28-3(CRP)]</measure>
    <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
    <description>The DAS28-3 (CRP) score is a measure of the perticipant's disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints) and CRP. DAS28-3 (CRP) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.
Change = value at observation minus value at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Based on 28-Joints Count Using Erythrocyte Sedimentation Rate [DAS28-4(ESR)]</measure>
    <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
    <description>The DAS28-4 (ESR) score is a measure of the participant's disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints), participant's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.
Change = score at observation minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Change = score at observation minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Painful and Tender Joint Counts</measure>
    <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
    <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joint Count (SJC)</measure>
    <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
    <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Assessment of Pain</measure>
    <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
    <description>Change from Baseline in Patient's Assessment of Arthritis Pain -VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) was computed as Week 2, 4, 8 or 12 values minus baseline value. A negative value in change from baseline indicates an improvement.
Change = value at observation minus value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient's Global Assessment of Arthritis</measure>
    <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly. Change = score at observation minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician's Global Assessment of Arthritis</measure>
    <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
    <description>Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no disease activity; very good and 100 mm = worst disease activity; very poor. Change = score at observation minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C- Reactive Protein (CRP) (mg/L)</measure>
    <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Change = value at observation minus value at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under Curve (AUC) for Change From Baseline in American College of Rheumatology-N (ACR-N)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>ACR-N = calculated for each participant by taking lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of remaining 5 components of ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The AUC for ACR-N is measure of the area under the curve of the mean change from baseline in ACR-N. The trapezoidal rule was used to compute AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Euro Quality of Life (EQ-5D)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Physical Functioning Domain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Physical Domain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Bodily Pain Domain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -General Health Domain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Vitality Domain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change =score at Week 12 minus score at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Social Functioning Domain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Emotional Domain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Mental Health Domain</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Physical Component Summary (PCS)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Mental Component Summary (MCS)</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">318</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP-690,550, 10mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP-690,550, 15mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP-690,550, 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP-690,550, 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>CP-690,550, 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo BID, 3 blinded tablets administered BID for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>10mg BID, 3 blinded tablets administered BID for 12 weeks</description>
    <arm_group_label>CP-690,550, 10mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>15mg BID, 3 blinded tablets administered BID for 12 weeks</description>
    <arm_group_label>CP-690,550, 15mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>1mg BID, 3 blinded tablets administered BID for 12 weeks</description>
    <arm_group_label>CP-690,550, 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>3mg BID, 3 blinded tablets administered BID for 12 weeks</description>
    <arm_group_label>CP-690,550, 3mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>5mg BID, 3 blinded tablets administered BID for 12 weeks</description>
    <arm_group_label>CP-690,550, 5mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have failed an adequate trial of therapy with at least 1 DMARD due to
             lack of efficacy or toxicity.

        Exclusion Criteria:

          -  Current therapy with any DMARD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Narashino</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Yotukaidou</city>
        <state>Chiba</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Iiduka</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kitakyusyu</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kurume</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sawara-ku</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Takasaki</city>
        <state>Gunma</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Higashihiroshima</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hiroshima-city</city>
        <state>Hiroshima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Asahikawa</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nishinomiya</city>
        <state>Hyogo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tsukuba</city>
        <state>Ibaraki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sagamihara</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Koushi</city>
        <state>Kumamoto</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tsu</city>
        <state>Mie</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sendai</city>
        <state>Miyagi</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ohmura</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sasebo</city>
        <state>Nagasaki</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ureshino-shi</city>
        <state>Saga</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kawagoe-shi</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kitamoto</city>
        <state>Saitama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Arakawa-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Musashimurayama-shi</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Setagaya-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Shinjyuku-ku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Takaoka</city>
        <state>Toyama</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chiba</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Fukusima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hiroshima</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nagasaki</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Oita</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saitama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921040&amp;StudyName=Comparison%20Of%205%20CP-690%2C550%20Doses%20Vs.%20Placebo%2C%20For%20The%20Treatment%20Of%20Rheumatoid%20Arthritis%20In%20Japan</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2008</study_first_posted>
  <results_first_submitted>November 26, 2012</results_first_submitted>
  <results_first_submitted_qc>November 26, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 25, 2012</results_first_posted>
  <disposition_first_submitted>November 19, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>November 19, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 29, 2010</disposition_first_posted>
  <last_update_submitted>March 19, 2013</last_update_submitted>
  <last_update_submitted_qc>March 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 2 monotherapy in Japan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP-690,550 1 mg</title>
          <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 3 mg</title>
          <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>CP-690,550 5 mg</title>
          <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>CP-690,550 10 mg</title>
          <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>CP-690,550 15 mg</title>
          <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Placebo</title>
          <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="53"/>
                <participants group_id="P5" count="54"/>
                <participants group_id="P6" count="52">One participant withdrew after randomization but prior to treatment.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="51"/>
                <participants group_id="P2" count="49"/>
                <participants group_id="P3" count="50"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="52"/>
                <participants group_id="P6" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP-690,550 1 mg</title>
          <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 3 mg</title>
          <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>CP-690,550 5 mg</title>
          <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>CP-690,550 10 mg</title>
          <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>CP-690,550 15 mg</title>
          <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="B6">
          <title>Placebo</title>
          <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="53"/>
            <count group_id="B2" value="53"/>
            <count group_id="B3" value="52"/>
            <count group_id="B4" value="53"/>
            <count group_id="B5" value="54"/>
            <count group_id="B6" value="52"/>
            <count group_id="B7" value="317"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt; 18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 44 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 45 and 64 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="31"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;= 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="44"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="44"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="264"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in painful and tender joint count; &gt;= 20% improvement in swollen joint count; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
        <time_frame>Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in painful and tender joint count; &gt;= 20% improvement in swollen joint count; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="36"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="49"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4 and 8</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in painful and tender joint count; &gt;= 20% improvement in swollen joint count; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP)at each visit.</description>
        <time_frame>Week 2, 4, and 8</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4 and 8</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in painful and tender joint count; &gt;= 20% improvement in swollen joint count; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP)at each visit.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="35"/>
                    <measurement group_id="O5" value="29"/>
                    <measurement group_id="O6" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="43"/>
                    <measurement group_id="O5" value="42"/>
                    <measurement group_id="O6" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="46"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
        <description>ACR50 response: greater than or equal to (&gt;=) 50 percent (%) improvement in painful and tender joint count; &gt;= 50% improvement in swollen joint count; and &gt;= 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP) at each visit.</description>
        <time_frame>Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
          <description>ACR50 response: greater than or equal to (&gt;=) 50 percent (%) improvement in painful and tender joint count; &gt;= 50% improvement in swollen joint count; and &gt;= 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP) at each visit.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="17"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="25"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="36"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="37"/>
                    <measurement group_id="O5" value="39"/>
                    <measurement group_id="O6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
        <description>ACR70 response: greater than or equal to (&gt;=) 70 percent (%) improvement in painful and tender joint count; &gt;= 70% improvement in swollen joint count; and &gt;= 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP) at each visit.</description>
        <time_frame>Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
          <description>ACR70 response: greater than or equal to (&gt;=) 70 percent (%) improvement in painful and tender joint count; &gt;= 70% improvement in swollen joint count; and &gt;= 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP) at each visit.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="9"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="20"/>
                    <measurement group_id="O5" value="22"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="28"/>
                    <measurement group_id="O6" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response</title>
        <description>ACR90 response: greater than or equal to (&gt;=) 90 percent (%) improvement in painful and tender joint count; &gt;= 90% improvement in swollen joint count; and &gt;= 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP) at each visit.</description>
        <time_frame>Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response</title>
          <description>ACR90 response: greater than or equal to (&gt;=) 90 percent (%) improvement in painful and tender joint count; &gt;= 90% improvement in swollen joint count; and &gt;= 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP) at each visit.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (LOCF)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Based on 28-Joints Count Using C-reactive Protein [DAS28-3(CRP)]</title>
        <description>The DAS28-3 (CRP) score is a measure of the perticipants disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints) and CRP. DAS28-3 (CRP) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.
Change = value at observation minus value at baseline</description>
        <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks. Missing values were not imputed.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Based on 28-Joints Count Using C-reactive Protein [DAS28-3(CRP)]</title>
          <description>The DAS28-3 (CRP) score is a measure of the perticipants disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints) and CRP. DAS28-3 (CRP) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.
Change = value at observation minus value at baseline</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=53, 53, 51, 52, 54, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.56" spread="0.13"/>
                    <measurement group_id="O2" value="-1.03" spread="0.13"/>
                    <measurement group_id="O3" value="-1.01" spread="0.13"/>
                    <measurement group_id="O4" value="-1.65" spread="0.13"/>
                    <measurement group_id="O5" value="-1.63" spread="0.13"/>
                    <measurement group_id="O6" value="-0.20" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=52, 51, 51, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.82" spread="0.13"/>
                    <measurement group_id="O2" value="-1.29" spread="0.13"/>
                    <measurement group_id="O3" value="-1.65" spread="0.13"/>
                    <measurement group_id="O4" value="-2.33" spread="0.13"/>
                    <measurement group_id="O5" value="-2.14" spread="0.13"/>
                    <measurement group_id="O6" value="-0.23" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=51, 51, 51, 52, 52, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.98" spread="0.13"/>
                    <measurement group_id="O2" value="-1.63" spread="0.13"/>
                    <measurement group_id="O3" value="-1.95" spread="0.13"/>
                    <measurement group_id="O4" value="-2.62" spread="0.13"/>
                    <measurement group_id="O5" value="-2.55" spread="0.13"/>
                    <measurement group_id="O6" value="-0.15" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 49, 50, 49, 52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.09" spread="0.13"/>
                    <measurement group_id="O2" value="-1.71" spread="0.13"/>
                    <measurement group_id="O3" value="-2.02" spread="0.13"/>
                    <measurement group_id="O4" value="-2.81" spread="0.13"/>
                    <measurement group_id="O5" value="-2.70" spread="0.13"/>
                    <measurement group_id="O6" value="-0.12" spread="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Based on 28-Joints Count Using Erythrocyte Sedimentation Rate [DAS28-4(ESR)]</title>
        <description>The DAS28-4 (ESR) score is a measure of the participants disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints), participants global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.
Change = score at observation minus score at baseline.</description>
        <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Based on 28-Joints Count Using Erythrocyte Sedimentation Rate [DAS28-4(ESR)]</title>
          <description>The DAS28-4 (ESR) score is a measure of the participants disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints), participants global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.
Change = score at observation minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=52, 53, 50, 52, 54, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="0.15"/>
                    <measurement group_id="O2" value="-0.93" spread="0.14"/>
                    <measurement group_id="O3" value="-1.00" spread="0.15"/>
                    <measurement group_id="O4" value="-1.66" spread="0.15"/>
                    <measurement group_id="O5" value="-1.58" spread="0.14"/>
                    <measurement group_id="O6" value="-0.25" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=52, 51, 51, 52, 52, 51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.79" spread="0.15"/>
                    <measurement group_id="O2" value="-1.32" spread="0.15"/>
                    <measurement group_id="O3" value="-1.69" spread="0.15"/>
                    <measurement group_id="O4" value="-2.42" spread="0.15"/>
                    <measurement group_id="O5" value="-2.31" spread="0.14"/>
                    <measurement group_id="O6" value="-0.23" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=51, 50, 51, 52, 52, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.03" spread="0.15"/>
                    <measurement group_id="O2" value="-1.68" spread="0.15"/>
                    <measurement group_id="O3" value="-2.05" spread="0.15"/>
                    <measurement group_id="O4" value="-2.92" spread="0.15"/>
                    <measurement group_id="O5" value="-2.87" spread="0.14"/>
                    <measurement group_id="O6" value="-0.12" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 49, 50, 49, 52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.10" spread="0.15"/>
                    <measurement group_id="O2" value="-1.74" spread="0.15"/>
                    <measurement group_id="O3" value="-2.20" spread="0.15"/>
                    <measurement group_id="O4" value="-3.05" spread="0.15"/>
                    <measurement group_id="O5" value="-2.98" spread="0.14"/>
                    <measurement group_id="O6" value="-0.10" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Change = score at observation minus score at baseline.</description>
        <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.
Change = score at observation minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=53, 53, 51, 52, 54, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.10" spread="0.06"/>
                    <measurement group_id="O2" value="-0.15" spread="0.06"/>
                    <measurement group_id="O3" value="-0.28" spread="0.06"/>
                    <measurement group_id="O4" value="-0.39" spread="0.06"/>
                    <measurement group_id="O5" value="-0.40" spread="0.06"/>
                    <measurement group_id="O6" value="0.06" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=52, 51, 51, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.07" spread="0.06"/>
                    <measurement group_id="O2" value="-0.25" spread="0.06"/>
                    <measurement group_id="O3" value="-0.38" spread="0.06"/>
                    <measurement group_id="O4" value="-0.54" spread="0.06"/>
                    <measurement group_id="O5" value="-0.51" spread="0.06"/>
                    <measurement group_id="O6" value="0.03" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=51, 50, 51, 52, 52, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.17" spread="0.06"/>
                    <measurement group_id="O2" value="-0.36" spread="0.06"/>
                    <measurement group_id="O3" value="-0.49" spread="0.06"/>
                    <measurement group_id="O4" value="-0.59" spread="0.06"/>
                    <measurement group_id="O5" value="-0.63" spread="0.06"/>
                    <measurement group_id="O6" value="0.18" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 49, 50, 49, 52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="0.06"/>
                    <measurement group_id="O2" value="-0.38" spread="0.06"/>
                    <measurement group_id="O3" value="-0.55" spread="0.06"/>
                    <measurement group_id="O4" value="-0.67" spread="0.06"/>
                    <measurement group_id="O5" value="-0.68" spread="0.06"/>
                    <measurement group_id="O6" value="0.18" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Painful and Tender Joint Counts</title>
        <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.</description>
        <time_frame>Baseline, Weeks 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Painful and Tender Joint Counts</title>
          <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=53, 53, 51, 52, 54, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.14" spread="0.98"/>
                    <measurement group_id="O2" value="-5.13" spread="0.97"/>
                    <measurement group_id="O3" value="-5.29" spread="0.99"/>
                    <measurement group_id="O4" value="-8.48" spread="0.98"/>
                    <measurement group_id="O5" value="-7.73" spread="0.96"/>
                    <measurement group_id="O6" value="-2.03" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=52, 51, 51, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.92" spread="0.98"/>
                    <measurement group_id="O2" value="-6.95" spread="0.98"/>
                    <measurement group_id="O3" value="-8.41" spread="0.99"/>
                    <measurement group_id="O4" value="-11.35" spread="0.98"/>
                    <measurement group_id="O5" value="-10.41" spread="0.97"/>
                    <measurement group_id="O6" value="-1.12" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=51, 51, 51, 52, 52, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.27" spread="0.98"/>
                    <measurement group_id="O2" value="-8.80" spread="0.98"/>
                    <measurement group_id="O3" value="-9.65" spread="0.99"/>
                    <measurement group_id="O4" value="-12.89" spread="0.98"/>
                    <measurement group_id="O5" value="-12.16" spread="0.97"/>
                    <measurement group_id="O6" value="-0.49" spread="0.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 49, 50, 49, 52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.05" spread="0.98"/>
                    <measurement group_id="O2" value="-10.01" spread="0.99"/>
                    <measurement group_id="O3" value="-10.08" spread="1.00"/>
                    <measurement group_id="O4" value="-13.67" spread="0.99"/>
                    <measurement group_id="O5" value="-12.81" spread="0.97"/>
                    <measurement group_id="O6" value="-0.67" spread="1.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joint Count (SJC)</title>
        <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.</description>
        <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Count (SJC)</title>
          <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=53, 53, 51, 52, 54, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.19" spread="0.69"/>
                    <measurement group_id="O2" value="-3.85" spread="0.68"/>
                    <measurement group_id="O3" value="-2.58" spread="0.70"/>
                    <measurement group_id="O4" value="-6.93" spread="0.69"/>
                    <measurement group_id="O5" value="-5.95" spread="0.68"/>
                    <measurement group_id="O6" value="-1.58" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=52, 51, 51, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.57" spread="0.69"/>
                    <measurement group_id="O2" value="-6.10" spread="0.69"/>
                    <measurement group_id="O3" value="-6.15" spread="0.70"/>
                    <measurement group_id="O4" value="-8.85" spread="0.69"/>
                    <measurement group_id="O5" value="-8.15" spread="0.68"/>
                    <measurement group_id="O6" value="-1.87" spread="0.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=51, 51, 51, 52, 52, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.25" spread="0.69"/>
                    <measurement group_id="O2" value="-7.08" spread="0.69"/>
                    <measurement group_id="O3" value="-7.15" spread="0.70"/>
                    <measurement group_id="O4" value="-10.04" spread="0.69"/>
                    <measurement group_id="O5" value="-10.52" spread="0.68"/>
                    <measurement group_id="O6" value="-1.70" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 49, 50, 49, 52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.76" spread="0.69"/>
                    <measurement group_id="O2" value="-7.94" spread="0.70"/>
                    <measurement group_id="O3" value="-7.75" spread="0.70"/>
                    <measurement group_id="O4" value="-10.44" spread="0.70"/>
                    <measurement group_id="O5" value="-10.73" spread="0.68"/>
                    <measurement group_id="O6" value="-1.29" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patients Assessment of Pain</title>
        <description>Change from Baseline in Patients Assessment of Arthritis Pain -VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) was computed as Week 2, 4, 8 or 12 values minus baseline value. A negative value in change from baseline indicates an improvement.
Change = value at observation minus value at baseline.</description>
        <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patients Assessment of Pain</title>
          <description>Change from Baseline in Patients Assessment of Arthritis Pain -VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) was computed as Week 2, 4, 8 or 12 values minus baseline value. A negative value in change from baseline indicates an improvement.
Change = value at observation minus value at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=53, 53, 51, 52, 54, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.63" spread="2.94"/>
                    <measurement group_id="O2" value="-16.70" spread="2.94"/>
                    <measurement group_id="O3" value="-19.13" spread="3.01"/>
                    <measurement group_id="O4" value="-29.03" spread="2.97"/>
                    <measurement group_id="O5" value="-26.45" spread="2.92"/>
                    <measurement group_id="O6" value="-1.46" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=52, 51, 51, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.97" spread="2.96"/>
                    <measurement group_id="O2" value="-21.19" spread="2.98"/>
                    <measurement group_id="O3" value="-26.06" spread="3.01"/>
                    <measurement group_id="O4" value="-36.65" spread="2.97"/>
                    <measurement group_id="O5" value="-35.16" spread="2.95"/>
                    <measurement group_id="O6" value="-2.73" spread="2.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=51, 50, 51, 52, 52, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.57" spread="2.97"/>
                    <measurement group_id="O2" value="-26.15" spread="2.99"/>
                    <measurement group_id="O3" value="-30.37" spread="3.01"/>
                    <measurement group_id="O4" value="-41.84" spread="2.97"/>
                    <measurement group_id="O5" value="-43.08" spread="2.95"/>
                    <measurement group_id="O6" value="1.65" spread="3.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 49, 50, 49, 52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.38" spread="2.97"/>
                    <measurement group_id="O2" value="-22.33" spread="3.00"/>
                    <measurement group_id="O3" value="-34.37" spread="3.02"/>
                    <measurement group_id="O4" value="-42.91" spread="3.01"/>
                    <measurement group_id="O5" value="-43.79" spread="2.95"/>
                    <measurement group_id="O6" value="-1.06" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patients Global Assessment of Arthritis</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly. Change = score at observation minus score at baseline.</description>
        <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patients Global Assessment of Arthritis</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly. Change = score at observation minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=53, 53, 51, 52, 54, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.66" spread="2.96"/>
                    <measurement group_id="O2" value="-15.25" spread="2.97"/>
                    <measurement group_id="O3" value="-20.32" spread="3.04"/>
                    <measurement group_id="O4" value="-27.06" spread="2.99"/>
                    <measurement group_id="O5" value="-26.80" spread="2.94"/>
                    <measurement group_id="O6" value="-1.73" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=52, 51, 51, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.22" spread="2.98"/>
                    <measurement group_id="O2" value="-23.17" spread="3.00"/>
                    <measurement group_id="O3" value="-27.03" spread="3.04"/>
                    <measurement group_id="O4" value="-36.64" spread="2.99"/>
                    <measurement group_id="O5" value="-35.96" spread="2.97"/>
                    <measurement group_id="O6" value="-3.31" spread="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=51, 50, 51, 52, 52, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.66" spread="2.99"/>
                    <measurement group_id="O2" value="-24.60" spread="3.01"/>
                    <measurement group_id="O3" value="-28.78" spread="3.04"/>
                    <measurement group_id="O4" value="-41.97" spread="2.99"/>
                    <measurement group_id="O5" value="-41.13" spread="2.97"/>
                    <measurement group_id="O6" value="0.79" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 49, 50, 49, 52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.29" spread="2.99"/>
                    <measurement group_id="O2" value="-20.91" spread="3.03"/>
                    <measurement group_id="O3" value="-34.59" spread="3.05"/>
                    <measurement group_id="O4" value="-43.55" spread="3.03"/>
                    <measurement group_id="O5" value="-41.86" spread="2.97"/>
                    <measurement group_id="O6" value="-1.02" spread="3.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physicians Global Assessment of Arthritis</title>
        <description>Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no disease activity; very good and 100 mm = worst disease activity; very poor. Change = score at observation minus score at baseline.</description>
        <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physicians Global Assessment of Arthritis</title>
          <description>Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no disease activity; very good and 100 mm = worst disease activity; very poor. Change = score at observation minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=53, 53, 51, 52, 54, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.97" spread="2.64"/>
                    <measurement group_id="O2" value="-15.86" spread="2.63"/>
                    <measurement group_id="O3" value="-18.10" spread="2.70"/>
                    <measurement group_id="O4" value="-31.59" spread="2.66"/>
                    <measurement group_id="O5" value="-25.93" spread="2.61"/>
                    <measurement group_id="O6" value="-6.09" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=52, 51, 51, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.31" spread="2.65"/>
                    <measurement group_id="O2" value="-26.22" spread="2.67"/>
                    <measurement group_id="O3" value="-30.45" spread="2.70"/>
                    <measurement group_id="O4" value="-41.21" spread="2.66"/>
                    <measurement group_id="O5" value="-37.07" spread="2.64"/>
                    <measurement group_id="O6" value="-9.70" spread="2.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=51, 51, 51, 52, 52, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.99" spread="2.66"/>
                    <measurement group_id="O2" value="-32.04" spread="2.67"/>
                    <measurement group_id="O3" value="-36.92" spread="2.70"/>
                    <measurement group_id="O4" value="-45.98" spread="2.66"/>
                    <measurement group_id="O5" value="-44.66" spread="2.64"/>
                    <measurement group_id="O6" value="-6.84" spread="2.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 49, 50, 49, 52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.38" spread="2.66"/>
                    <measurement group_id="O2" value="-33.47" spread="2.69"/>
                    <measurement group_id="O3" value="-36.89" spread="2.71"/>
                    <measurement group_id="O4" value="-49.38" spread="2.70"/>
                    <measurement group_id="O5" value="-48.36" spread="2.64"/>
                    <measurement group_id="O6" value="-8.35" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C- Reactive Protein (CRP) (mg/L)</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Change = value at observation minus value at baseline.</description>
        <time_frame>Baseline, Week 2, 4, 8 and 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C- Reactive Protein (CRP) (mg/L)</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Change = value at observation minus value at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>mg/L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2 (n=53, 53, 51, 52, 54, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.69" spread="2.24"/>
                    <measurement group_id="O2" value="-16.61" spread="2.24"/>
                    <measurement group_id="O3" value="-17.32" spread="2.29"/>
                    <measurement group_id="O4" value="-22.50" spread="2.26"/>
                    <measurement group_id="O5" value="-24.95" spread="2.22"/>
                    <measurement group_id="O6" value="1.02" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=52, 51, 51, 52, 52, 52)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.56" spread="2.25"/>
                    <measurement group_id="O2" value="-16.26" spread="2.27"/>
                    <measurement group_id="O3" value="-22.20" spread="2.29"/>
                    <measurement group_id="O4" value="-24.47" spread="2.26"/>
                    <measurement group_id="O5" value="-24.59" spread="2.25"/>
                    <measurement group_id="O6" value="0.59" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=51, 51, 51, 52, 52, 50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.79" spread="2.27"/>
                    <measurement group_id="O2" value="-16.71" spread="2.27"/>
                    <measurement group_id="O3" value="-23.80" spread="2.29"/>
                    <measurement group_id="O4" value="-23.56" spread="2.26"/>
                    <measurement group_id="O5" value="-26.03" spread="2.25"/>
                    <measurement group_id="O6" value="5.27" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (n=51, 49, 50, 49, 52, 48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.88" spread="2.27"/>
                    <measurement group_id="O2" value="-18.34" spread="2.30"/>
                    <measurement group_id="O3" value="-23.97" spread="2.30"/>
                    <measurement group_id="O4" value="-25.11" spread="2.30"/>
                    <measurement group_id="O5" value="-26.14" spread="2.25"/>
                    <measurement group_id="O6" value="8.22" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under Curve (AUC) for Change From Baseline in American College of Rheumatology-N (ACR-N)</title>
        <description>ACR-N = calculated for each participant by taking lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of remaining 5 components of ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The AUC for ACR-N is measure of the area under the curve of the mean change from baseline in ACR-N. The trapezoidal rule was used to compute AUC.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under Curve (AUC) for Change From Baseline in American College of Rheumatology-N (ACR-N)</title>
          <description>ACR-N = calculated for each participant by taking lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of remaining 5 components of ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The AUC for ACR-N is measure of the area under the curve of the mean change from baseline in ACR-N. The trapezoidal rule was used to compute AUC.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="53"/>
                <count group_id="O5" value="54"/>
                <count group_id="O6" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="498.47" spread="341.96"/>
                    <measurement group_id="O2" value="1876.4" spread="341.96"/>
                    <measurement group_id="O3" value="2573.0" spread="345.23"/>
                    <measurement group_id="O4" value="3887.4" spread="341.96"/>
                    <measurement group_id="O5" value="3628.9" spread="338.78"/>
                    <measurement group_id="O6" value="-2415" spread="345.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Euro Quality of Life (EQ-5D)</title>
        <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Euro Quality of Life (EQ-5D)</title>
          <description>EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (&quot;confined to bed&quot;). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="0.03"/>
                    <measurement group_id="O2" value="0.21" spread="0.03"/>
                    <measurement group_id="O3" value="0.28" spread="0.03"/>
                    <measurement group_id="O4" value="0.33" spread="0.03"/>
                    <measurement group_id="O5" value="0.33" spread="0.03"/>
                    <measurement group_id="O6" value="-0.04" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Physical Functioning Domain</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Physical Functioning Domain</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.62" spread="1.09"/>
                    <measurement group_id="O2" value="6.23" spread="1.11"/>
                    <measurement group_id="O3" value="5.83" spread="1.13"/>
                    <measurement group_id="O4" value="9.59" spread="1.11"/>
                    <measurement group_id="O5" value="8.61" spread="1.08"/>
                    <measurement group_id="O6" value="-2.53" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Physical Domain</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Physical Domain</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.15" spread="1.18"/>
                    <measurement group_id="O2" value="4.42" spread="1.20"/>
                    <measurement group_id="O3" value="6.17" spread="1.21"/>
                    <measurement group_id="O4" value="8.91" spread="1.20"/>
                    <measurement group_id="O5" value="7.77" spread="1.17"/>
                    <measurement group_id="O6" value="-0.72" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Bodily Pain Domain</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Bodily Pain Domain</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.94" spread="1.08"/>
                    <measurement group_id="O2" value="7.81" spread="1.10"/>
                    <measurement group_id="O3" value="9.74" spread="1.11"/>
                    <measurement group_id="O4" value="12.58" spread="1.10"/>
                    <measurement group_id="O5" value="13.90" spread="1.07"/>
                    <measurement group_id="O6" value="0.27" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -General Health Domain</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -General Health Domain</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" spread="0.84"/>
                    <measurement group_id="O2" value="4.76" spread="0.86"/>
                    <measurement group_id="O3" value="5.37" spread="0.86"/>
                    <measurement group_id="O4" value="7.57" spread="0.86"/>
                    <measurement group_id="O5" value="7.61" spread="0.83"/>
                    <measurement group_id="O6" value="0.16" spread="0.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Vitality Domain</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change =score at Week 12 minus score at baseline</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg BID</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Vitality Domain</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change =score at Week 12 minus score at baseline</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" spread="0.74"/>
                    <measurement group_id="O2" value="6.11" spread="0.76"/>
                    <measurement group_id="O3" value="6.58" spread="0.77"/>
                    <measurement group_id="O4" value="11.98" spread="0.77"/>
                    <measurement group_id="O5" value="9.49" spread="0.74"/>
                    <measurement group_id="O6" value="3.38" spread="0.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Social Functioning Domain</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Social Functioning Domain</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.22" spread="1.21"/>
                    <measurement group_id="O2" value="4.88" spread="1.24"/>
                    <measurement group_id="O3" value="4.65" spread="1.24"/>
                    <measurement group_id="O4" value="4.56" spread="1.24"/>
                    <measurement group_id="O5" value="7.62" spread="1.20"/>
                    <measurement group_id="O6" value="-0.67" spread="1.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Emotional Domain</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Emotional Domain</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.83" spread="1.41"/>
                    <measurement group_id="O2" value="4.20" spread="1.44"/>
                    <measurement group_id="O3" value="5.64" spread="1.44"/>
                    <measurement group_id="O4" value="7.99" spread="1.44"/>
                    <measurement group_id="O5" value="6.42" spread="1.40"/>
                    <measurement group_id="O6" value="-1.50" spread="1.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Mental Health Domain</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Mental Health Domain</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="1.29"/>
                    <measurement group_id="O2" value="5.02" spread="1.32"/>
                    <measurement group_id="O3" value="8.62" spread="1.32"/>
                    <measurement group_id="O4" value="7.64" spread="1.32"/>
                    <measurement group_id="O5" value="6.27" spread="1.28"/>
                    <measurement group_id="O6" value="0.59" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Physical Component Summary (PCS)</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Physical Component Summary (PCS)</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="0.86"/>
                    <measurement group_id="O2" value="6.03" spread="0.88"/>
                    <measurement group_id="O3" value="6.22" spread="0.89"/>
                    <measurement group_id="O4" value="10.25" spread="0.88"/>
                    <measurement group_id="O5" value="10.27" spread="0.85"/>
                    <measurement group_id="O6" value="-1.04" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Mental Component Summary (MCS)</title>
        <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
        <group_list>
          <group group_id="O1">
            <title>CP-690,550 1 mg</title>
            <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 3 mg</title>
            <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 5 mg</title>
            <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>CP-690,550 10 mg</title>
            <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O5">
            <title>CP-690,550 15 mg</title>
            <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
          <group group_id="O6">
            <title>Placebo</title>
            <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Mental Component Summary (MCS)</title>
          <description>SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).
Change = score at Week 12 minus score at baseline.</description>
          <population>The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="50"/>
                <count group_id="O4" value="49"/>
                <count group_id="O5" value="52"/>
                <count group_id="O6" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="1.27"/>
                    <measurement group_id="O2" value="3.99" spread="1.30"/>
                    <measurement group_id="O3" value="7.09" spread="1.30"/>
                    <measurement group_id="O4" value="6.15" spread="1.30"/>
                    <measurement group_id="O5" value="5.52" spread="1.26"/>
                    <measurement group_id="O6" value="0.15" spread="1.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP-690,550 1 mg</title>
          <description>Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 3 mg</title>
          <description>Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>CP-690,550 5 mg</title>
          <description>Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>CP-690,550 10 mg</title>
          <description>Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>CP-690,550 15 mg</title>
          <description>Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Placebo</title>
          <description>Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Herpes zoster oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="19" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="22" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="16" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Low density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="52"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="52"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

